Mono Pharmacare Valuation

Is MONOPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MONOPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MONOPHARMA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MONOPHARMA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MONOPHARMA?

Key metric: As MONOPHARMA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MONOPHARMA. This is calculated by dividing MONOPHARMA's market cap by their current earnings.
What is MONOPHARMA's PE Ratio?
PE Ratio	24x
Earnings	₹24.42m
Market Cap	₹587.48m

MONOPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	15.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does MONOPHARMA's PE Ratio compare to its peers?

The above table shows the PE ratio for MONOPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.9x
542934 Chandra Bhagat Pharma	32.9x	n/a	₹520.6m
539938 Medico Intercontinental	12.9x	n/a	₹557.2m
543594 Dipna Pharmachem	15x	n/a	₹162.3m
543916 Hemant Surgical Industries	15x	n/a	₹1.3b
MONOPHARMA Mono Pharmacare	24x	n/a	₹587.5m

Price-To-Earnings vs Peers: MONOPHARMA is expensive based on its Price-To-Earnings Ratio (24x) compared to the peer average (18.9x).

Price to Earnings Ratio vs Industry

How does MONOPHARMA's PE Ratio compare vs other companies in the IN Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
523696 Fortis Malar Hospitals	2.1x	n/a	US$11.88m
542918 Gian Life Care	4.8x	n/a	US$2.32m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: MONOPHARMA is good value based on its Price-To-Earnings Ratio (24x) compared to the Indian Healthcare industry average (42.6x).

Price to Earnings Ratio vs Fair Ratio

What is MONOPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MONOPHARMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	24x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MONOPHARMA's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medico Intercontinental

₹557.2m

Trades in pharmaceutical products.

539938

₹61.29

33.1%

-27.8%

Dr Lalchandani Labs

₹81.2m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.73

4.1%

-46.5%

N G Industries

₹566.9m

Provides various healthcare services in India.

530897

₹168.05

0.2%

2.7%